New combo therapy aims to tame throat cancer with fewer side effects
NCT ID NCT07578467
First seen May 13, 2026 · Last updated Jun 23, 2026 · Updated 5 times
Summary
This study tests a new drug called ATRN-119 combined with a single, highly focused dose of radiation for people with early-stage HPV-positive throat cancer. The goal is to shrink tumors before surgery while reducing long-term side effects. About 35 participants will take the drug daily for 10 days and receive one radiation treatment on day 3, followed by standard surgery. Researchers will check if the treatment is safe and how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV ASSOCIATED CANCERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ATRN-119 (a drug that blocks a protein called ATR) plus stereotactic body radiation therapy (SBRT)
What this could lead to
If it works, this approach could offer a less toxic treatment option for early-stage HPV-positive throat cancer, preserving quality of life while keeping cure rates high.
What could go wrong
This is an early-phase trial with only 35 participants, so results may not apply to everyone. The drug and radiation combination could cause unexpected side effects or fail to improve outcomes over standard care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.